BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the BioCryst Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioCryst Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioCryst Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioCryst Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BioCryst Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate BioCryst Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioCryst Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioCryst Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioCryst Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioCryst Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of BioCryst Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
BioCryst Pharmaceuticals, Inc. Snapshot 5
BioCryst Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
BioCryst Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
BioCryst Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
BioCryst Pharmaceuticals, Inc. - Pipeline Products Glance 11
BioCryst Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
BioCryst Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
BioCryst Pharmaceuticals, Inc. - Drug Profiles 15
BCX-4161 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
BCX-4430 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
BCX-7353 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
BCX-xxxx 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
BioCryst Pharmaceuticals, Inc. - Pipeline Analysis 21
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Target 21
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 22
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 23
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 24
BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates 25
BioCryst Pharmaceuticals, Inc. - Dormant Projects 29
BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
BCX-5191 30
peldesine 30
BioCryst Pharmaceuticals, Inc. - Company Statement 31
BioCryst Pharmaceuticals, Inc. - Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables

BioCryst Pharmaceuticals, Inc., Key Information 5
BioCryst Pharmaceuticals, Inc., Key Facts 5
BioCryst Pharmaceuticals, Inc. - Pipeline by Indication, 2015 6
BioCryst Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 7
BioCryst Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 8
BioCryst Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015 9
BioCryst Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 10
BioCryst Pharmaceuticals, Inc. - Phase II, 2015 11
BioCryst Pharmaceuticals, Inc. - Phase I, 2015 12
BioCryst Pharmaceuticals, Inc. - Preclinical, 2015 13
BioCryst Pharmaceuticals, Inc. - Discovery, 2015 14
BioCryst Pharmaceuticals, Inc. - Pipeline by Target, 2015 21
BioCryst Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 22
BioCryst Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 23
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 24
BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 25
BioCryst Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 29
BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 30
BioCryst Pharmaceuticals, Inc., Other Locations 35
BioCryst Pharmaceuticals, Inc., Subsidiaries 35